ASN-007 clinical trials
Also written ERAS-007.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2018
How each study uses ASN-007 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- ERAS-007
- 3
Studies by the year they started
4 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2021 | 2 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses ASN-007 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid TumorsCompletedPhase 1/2Erasca, Inc.NCT04866134Written as ERAS-007
- A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLCCompletedPhase 1Erasca, Inc.NCT04959981Written as ERAS-007
- A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic MalignanciesWithdrawnPhase 1/2Erasca, Inc.NCT05279859Written as ERAS-007
- A Study of ASN007 in Patients With Advanced Solid TumorsCompletedPhase 1Asana BioSciencesNCT03415126Written as ASN007: ascending doses
Given beside what is tested · 1 — ASN-007 is usual care or a partner of the new treatment
Codes
What other systems call ASN-007 · ClinicalTrials.gg INT019028
- UNII (FDA) 6EEK33O4O4ASN-007One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 6EEK33O4O4 | ASN-007 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.